COVID-19治疗的全面回顾

IF 0.3 Q3 MEDICINE, GENERAL & INTERNAL
Z. Afshar, A. Babazadeh, M. Javanian, M. Barary, Vasigala Rekha, S. Ebrahimpour
{"title":"COVID-19治疗的全面回顾","authors":"Z. Afshar, A. Babazadeh, M. Javanian, M. Barary, Vasigala Rekha, S. Ebrahimpour","doi":"10.5937/afmnai38-26326","DOIUrl":null,"url":null,"abstract":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus strain that caused coronavirus disease 2019 (COVID-19). This novel coronavirus is an emerging global health threat. It caused approximately 140 million confirmed cases, with about 3 million deaths worldwide until April 18, 2021. Although there are two approved medications for this disease, remdesivir and dexamethasone, numerous studies are underway to investigate more therapeutic options. However, so far, most treatments have been supportive, and the clinical efficacy of the suggested drugs is still under consideration. The purpose of this review is to summarize the ongoing treatments, such as several antivirals, convalescent plasma transfusion, and adjunctive medications, with the intent of serving as a clinical guide for the physician and a resource for further evaluations in various clinical trials.","PeriodicalId":7132,"journal":{"name":"Acta Facultatis Medicae Naissensis","volume":"1 1","pages":""},"PeriodicalIF":0.3000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"A comprehensive review of COVID-19 treatment\",\"authors\":\"Z. Afshar, A. Babazadeh, M. Javanian, M. Barary, Vasigala Rekha, S. Ebrahimpour\",\"doi\":\"10.5937/afmnai38-26326\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus strain that caused coronavirus disease 2019 (COVID-19). This novel coronavirus is an emerging global health threat. It caused approximately 140 million confirmed cases, with about 3 million deaths worldwide until April 18, 2021. Although there are two approved medications for this disease, remdesivir and dexamethasone, numerous studies are underway to investigate more therapeutic options. However, so far, most treatments have been supportive, and the clinical efficacy of the suggested drugs is still under consideration. The purpose of this review is to summarize the ongoing treatments, such as several antivirals, convalescent plasma transfusion, and adjunctive medications, with the intent of serving as a clinical guide for the physician and a resource for further evaluations in various clinical trials.\",\"PeriodicalId\":7132,\"journal\":{\"name\":\"Acta Facultatis Medicae Naissensis\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Facultatis Medicae Naissensis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5937/afmnai38-26326\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Facultatis Medicae Naissensis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5937/afmnai38-26326","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 3

摘要

严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)是导致2019冠状病毒病(COVID-19)的病毒株。这种新型冠状病毒是一种新兴的全球健康威胁。截至2021年4月18日,它在全球造成约1.4亿确诊病例,约300万人死亡。尽管目前有两种已获批准的治疗此病的药物,瑞德西韦和地塞米松,但仍有许多研究正在进行中,以探索更多的治疗选择。然而,到目前为止,大多数治疗都是支持性的,推荐药物的临床疗效仍在考虑中。本综述的目的是总结正在进行的治疗,如几种抗病毒药物,恢复期血浆输注和辅助药物,旨在为医生提供临床指导,并为各种临床试验的进一步评估提供资源。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A comprehensive review of COVID-19 treatment
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus strain that caused coronavirus disease 2019 (COVID-19). This novel coronavirus is an emerging global health threat. It caused approximately 140 million confirmed cases, with about 3 million deaths worldwide until April 18, 2021. Although there are two approved medications for this disease, remdesivir and dexamethasone, numerous studies are underway to investigate more therapeutic options. However, so far, most treatments have been supportive, and the clinical efficacy of the suggested drugs is still under consideration. The purpose of this review is to summarize the ongoing treatments, such as several antivirals, convalescent plasma transfusion, and adjunctive medications, with the intent of serving as a clinical guide for the physician and a resource for further evaluations in various clinical trials.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Acta Facultatis Medicae Naissensis
Acta Facultatis Medicae Naissensis MEDICINE, GENERAL & INTERNAL-
CiteScore
0.70
自引率
0.00%
发文量
13
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信